Simplex Trading
QNCX icon

Simplex Trading’s Quince Therapeutics QNCX Stock Holding History

Simplex Trading’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-770
Closed -$15.6K – 10118
2026
Q1 		$15.6K Sell
770
-66
-8% -$13.2K ﹤0.01% 6966
2025
Q4 		$560K Buy
836
+393
+89% +$198K ﹤0.01% 3190
2025
Q3 		$144K Buy
+443
New +$148K ﹤0.01% 5331
2024
Q3 		– Sell
-11
Closed -$1.58K – 9360
2024
Q2 		$1K Sell
11
-13
-54% -$2.35K ﹤0.01% 8541
2024
Q1 		$4K Buy
24
+21
+700% +$5.22K ﹤0.01% 8150
2023
Q4 		$0 Buy
+3
New +$601 ﹤0.01% 9623
2023
Q1 		– Sell
-332
Closed -$65K – 9917
2022
Q4 		$42K Buy
332
+49
+17% +$8.19K ﹤0.01% 6086
2022
Q3 		$75K Sell
283
-7
-2% -$2.67K ﹤0.01% 5900
2022
Q2 		$128K Buy
+290
New +$205K ﹤0.01% 5227
2020
Q4 		– Sell
-6
Closed -$53.2K – 8917
2020
Q3 		$63K Buy
+6
New +$54.6K ﹤0.01% 5389

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Simplex Trading's QNCX Position: Q2 2026 in Review

Simplex Trading sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 770 shares — an estimated $15.6K sold.

Simplex Trading first reported a position in QNCX in Q3 2020 and held it in 10 quarters. The position peaked at $560K in Q4 2025. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Simplex Trading reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 770 Quince Therapeutics shares in Q2 2026, an estimated $15.6K.
  • Simplex Trading first reported a position in Quince Therapeutics in Q3 2020 and held it in 10 quarters.
  • Simplex Trading's Quince Therapeutics position peaked at $560K in Q4 2025.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.